Headquartered in Melbourne, VIC·Fiscal year ends June·NASDAQ: MESO·mesoblast.com
About Mesoblast
Mesoblast is a biotechnology company that develops allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's proprietary mesenchymal lineage cell therapy technology platform produces therapies that respond to severe inflammation by releasing anti-inflammatory factors that modulate multiple effector arms of the immune system. Mesoblast's flagship product, Ryoncil (remestemcel-L-rknd), is the first FDA-approved mesenchymal stromal cell (MSC) therapy, currently approved for pediatric patients aged 2 months and older with steroid-refractory acute graft versus host disease. The company is pursuing label expansion of Ryoncil into adults with SR-aGvHD and pediatric Duchenne muscular dystrophy. Its second platform product, rexlemestrocel-L, is in Phase 3 development for chronic low back pain associated with degenerative disc disease and is being filed with FDA for end-stage heart failure patients on left ventricular assist devices. Mesoblast holds a global intellectual property portfolio of over 1,100 granted patents and patent applications providing protection through at least 2044, and has established commercial partnerships in Japan (JCR Pharmaceuticals), Europe/Latin America (Grünenthal for CLBP), and China (Tasly Pharmaceuticals for heart failure). The company is listed on the ASX (MSB) and Nasdaq (MESO). Updated
More and more companies are joining the fight against the coronavirus, and 24/7 Wall St. is taking a look at some of the biggest movers on the day tied to COVID-19.
Mesoblast is a biotechnology company that develops allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions.
What is the MESO stock price target?
The Wall Street consensus 12-month price target for MESO is $37.00.
Chris Lange